Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mogami, Tae ^a,b   Yokota, Naho ^b   Asai Sato, Mikiko ^b   Yamada, Roppei ^a   Koizume, Shiro ^a   Sakuma, Yuji ^a   Yoshihara, Mitsuyo ^a   Nakamura, Yoshiyasu ^a   Takano, Yasuo ^a   Hirahara, Fumiki ^b   Miyagi, Yohei ^a   Miyagi, Etsuko ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; LIPOCORTIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEMBRANE PROTEIN; PACLITAXEL; RHAMM PROTEIN; UNCLASSIFIED DRUG; HERMES ANTIGEN; HYALURONAN-MEDIATED MOTILITY RECEPTOR; LAMP2 PROTEIN, HUMAN; SCLEROPROTEIN;

ACIDITY; ADJUVANT THERAPY; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOELECTRIC POINT; OVARIECTOMY; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; UPREGULATION; ADENOCARCINOMA; CELL MOTION; DRUG RESISTANCE; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ANNEXIN A4; ANTIGENS, CD44; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; ISOELECTRIC POINT; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84893187301     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080359     Document Type: Article

References (33)

1. Gurung A, Hung T, Morin J, Gilks CB (2013) Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 62: 59-70.
2. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, et al. (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374. (Pubitemid 43772268)
3. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121: 407-415.
4. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729.
5. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, et al. (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512. (Pubitemid 37466491)
6. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, et al. (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116-6126. (Pubitemid 41262937)
7. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430. (Pubitemid 41338978)
8. Miao Y, Cai B, Liu L, Yang Y, Wan X (2009) Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 19: 1545-1549.
9. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, et al. (2010) Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 29: 1741-1752.
10. Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, et al. (2006) Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6: 5880-5890. (Pubitemid 44764024)
11. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, et al. (2009) Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 125: 2316-2322.
12. Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, et al. (2012) Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci 103: 747-755.
13. Gerke V, Creutz CE, Moss SE (2005) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449-461. (Pubitemid 40780557)
14. Mussunoor S, Murray GI (2008) The role of annexins in tumour development and progression. J Pathol 216: 131-140.
15. Kim A, Serada S, Enomoto T, Naka T (2010) Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets 14: 963-971.
16. Lin LL, Huang HC, Juan HF (2012) Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays. PLoS One 7: e44615.
17. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98: 426-433. (Pubitemid 351161239)
18. Alfonso P, Canamero M, Fernandez-Carbonie F, Nunez A, Casal JI (2008) Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 7: 4247-4255.
19. Deng S, Wang J, Hou L, Li J, Chen G, et al. (2013) Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett 5: 107-112.
20. Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, et al. (2013) Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol 44: 1017-1023.
21. Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, et al. (2004) Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 209: 111-118. (Pubitemid 38625750)
22. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC (2000) Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 83: 83-88. (Pubitemid 30352721)
23. Yanagibashi T, Gorai I, Nakazawa T, Miyagi E, Hirahara F, et al. (1997) Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br J Cancer 76: 829-835. (Pubitemid 27401931)
24. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576. (Pubitemid 26135897)
25. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, et al. (2009) Selfproduction of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 101: 2023-2029.
26. Lin LL, Chen CN, Lin WC, Lee PH, Chang KJ, et al. (2008) Annexin A4: A novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl 2: 619-634.
27. Shigetomi H, Tsunemi T, Haruta S, Kajihara H, Yoshizawa Y, et al. (2012) Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities. Cancer Invest 30: 473-480.
28. Ortiz-Zapater E, Peiro S, Roda O, Corominas JM, Aguilar S, et al. (2007) Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol 170: 1573-1584. (Pubitemid 47339302)
29. Khau T, Langenbach SY, Schuliga M, Harris T, Johnstone CN, et al. (2011) Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. FASEB J 25: 483-496.
30. Masuishi Y, Arakawa N, Kawasaki H, Miyagi E, Hirahara F, et al. (2011) Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma. FEBS J 278: 1470-1483.
31. Hall CL, Wang C, Lange LA, Turley EA (1994) Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J Cell Biol 126: 575-588. (Pubitemid 24226272)
32. Foley JP, Lam D, Jiang H, Liao J, Cheong N, et al. (2012) Toll-like receptor 2 (TLR2), transforming growth factor-beta, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis. J Biol Chem 287: 37406-37419.
33. Sarafian V, Jadot M, Foidart JM, Letesson JJ, Van den Brule F, et al. (1998) Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int J Cancer 75: 105-111. (Pubitemid 28113984)